Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk.

Petitalot A, Dardillac E, Jacquet E, Nhiri N, Guirouilh-Barbat J, Julien P, Bouazzaoui I, Bonte D, Feunteun J, Schnell JA, Lafitte P, Aude JC, Noguès C, Rouleau E, Lidereau R, Lopez BS, Zinn-Justin S, Caputo SM; UNICANCER Genetic Group BRCA network.

Mol Cancer Res. 2019 Jan;17(1):54-69. doi: 10.1158/1541-7786.MCR-17-0357. Epub 2018 Sep 26.

PMID:
30257991
2.

Steroid hormone profiling in human breast adipose tissue using semi-automated purification and highly sensitive determination of estrogens by GC-APCI-MS/MS.

Hennig K, Antignac JP, Bichon E, Morvan ML, Miran I, Delaloge S, Feunteun J, Le Bizec B.

Anal Bioanal Chem. 2018 Jan;410(1):259-275. doi: 10.1007/s00216-017-0717-8. Epub 2017 Nov 16.

PMID:
29147745
3.

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.

Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B.

J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7.

4.

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A.

Sci Transl Med. 2016 Dec 14;8(369):369ra177.

PMID:
27974665
5.

BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.

Wang H, Bierie B, Li AG, Pathania S, Toomire K, Dimitrov SD, Liu B, Gelman R, Giobbie-Hurder A, Feunteun J, Polyak K, Livingston DM.

Mol Cell. 2016 Jul 21;63(2):277-292. doi: 10.1016/j.molcel.2016.05.038. Epub 2016 Jun 30.

6.

Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.

Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A.

Oncotarget. 2016 Jul 19;7(29):45317-45330. doi: 10.18632/oncotarget.9638.

7.

Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F.

Ann Oncol. 2016 Aug;27(8):1443-8. doi: 10.1093/annonc/mdw192. Epub 2016 May 3.

PMID:
27143638
8.

Role of the BAHD1 Chromatin-Repressive Complex in Placental Development and Regulation of Steroid Metabolism.

Lakisic G, Lebreton A, Pourpre R, Wendling O, Libertini E, Radford EJ, Le Guillou M, Champy MF, Wattenhofer-Donzé M, Soubigou G, Ait-Si-Ali S, Feunteun J, Sorg T, Coppée JY, Ferguson-Smith AC, Cossart P, Bierne H.

PLoS Genet. 2016 Mar 3;12(3):e1005898. doi: 10.1371/journal.pgen.1005898. eCollection 2016 Mar.

9.

Effect of PALB2 status on breast cancer precision medicine.

Delaloge S, Caron O, Feunteun J.

Lancet Oncol. 2015 Jun;16(6):598-600. doi: 10.1016/S1470-2045(15)70182-8. Epub 2015 May 7. No abstract available.

PMID:
25959804
10.

BRCA1 haploinsufficiency for replication stress suppression in primary cells.

Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, Livingston DM.

Nat Commun. 2014 Nov 17;5:5496. doi: 10.1038/ncomms6496.

11.

Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.

Couvé S, Ladroue C, Laine E, Mahtouk K, Guégan J, Gad S, Le Jeune H, Le Gentil M, Nuel G, Kim WY, Lecomte B, Pagès JC, Collin C, Lasne F, Benusiglio PR, Bressac-de Paillerets B, Feunteun J, Lazar V, Gimenez-Roqueplo AP, Mazure NM, Dessen P, Tchertanov L, Mole DR, Kaelin W, Ratcliffe P, Richard S, Gardie B.

Cancer Res. 2014 Nov 15;74(22):6554-64. doi: 10.1158/0008-5472.CAN-14-1161. Epub 2014 Nov 4.

12.

BRCA1 is required for postreplication repair after UV-induced DNA damage.

Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, Feunteun J, Livingston DM.

Mol Cell. 2011 Oct 21;44(2):235-51. doi: 10.1016/j.molcel.2011.09.002. Epub 2011 Sep 29.

13.

Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.

Ladroue C, Hoogewijs D, Gad S, Carcenac R, Storti F, Barrois M, Gimenez-Roqueplo AP, Leporrier M, Casadevall N, Hermine O, Kiladjian JJ, Baruchel A, Fakhoury F, Bressac-de Paillerets B, Feunteun J, Mazure N, Pouysségur J, Wenger RH, Richard S, Gardie B.

Haematologica. 2012 Jan;97(1):9-14. doi: 10.3324/haematol.2011.044644. Epub 2011 Sep 20.

14.

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.

Gardie B, Remenieras A, Kattygnarath D, Bombled J, Lefèvre S, Perrier-Trudova V, Rustin P, Barrois M, Slama A, Avril MF, Bessis D, Caron O, Caux F, Collignon P, Coupier I, Cremin C, Dollfus H, Dugast C, Escudier B, Faivre L, Field M, Gilbert-Dussardier B, Janin N, Leport Y, Leroux D, Lipsker D, Malthieu F, McGilliwray B, Maugard C, Méjean A, Mortemousque I, Plessis G, Poppe B, Pruvost-Balland C, Rooker S, Roume J, Soufir N, Steinraths M, Tan MH, Théodore C, Thomas L, Vabres P, Van Glabeke E, Meric JB, Verkarre V, Lenoir G, Joulin V, Deveaux S, Cusin V, Feunteun J, Teh BT, Bressac-de Paillerets B, Richard S; French National Cancer Institute "Inherited predisposition to kidney cancer" network.

J Med Genet. 2011 Apr;48(4):226-34. doi: 10.1136/jmg.2010.085068. Epub 2011 Mar 12. Erratum in: J Med Genet. 2011 Aug;48(8):576.

15.

Human BAHD1 promotes heterochromatic gene silencing.

Bierne H, Tham TN, Batsche E, Dumay A, Leguillou M, Kernéis-Golsteyn S, Regnault B, Seeler JS, Muchardt C, Feunteun J, Cossart P.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13826-31. doi: 10.1073/pnas.0901259106. Epub 2009 Aug 3.

16.

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.

Manié E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de Thé H, Stoppa-Lyonnet D, Stern MH.

Cancer Res. 2009 Jan 15;69(2):663-71. doi: 10.1158/0008-5472.CAN-08-1560. Erratum in: Cancer Res. 2009 Apr 1;69(7):3240.

17.

PHD2 mutation and congenital erythrocytosis with paraganglioma.

Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, Feunteun J, Pouysségur J, Richard S, Gardie B.

N Engl J Med. 2008 Dec 18;359(25):2685-92. doi: 10.1056/NEJMoa0806277.

18.

Further evidence for BRCA1 communication with the inactive X chromosome.

Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, Livingston DM.

Cell. 2007 Mar 9;128(5):991-1002.

19.

Heterozygote BRCA1 status and skewed chromosome X inactivation.

Helbling-Leclere A, Lenoir GM, Feunteun J.

Fam Cancer. 2007;6(1):153-7.

PMID:
16944269
20.

Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.

Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM.

Cold Spring Harb Symp Quant Biol. 2005;70:93-7.

PMID:
16869742
21.

PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.

Luciani JJ, Depetris D, Usson Y, Metzler-Guillemain C, Mignon-Ravix C, Mitchell MJ, Megarbane A, Sarda P, Sirma H, Moncla A, Feunteun J, Mattei MG.

J Cell Sci. 2006 Jun 15;119(Pt 12):2518-31. Epub 2006 May 30.

22.

[Hereditary predisposition to cancer].

Feunteun J.

Bull Acad Natl Med. 2005 May;189(5):797-800. French.

PMID:
16433452
23.

Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy.

Clavel J, Bellec S, Rebouissou S, Ménégaux F, Feunteun J, Bonaïti-Pellié C, Baruchel A, Kebaili K, Lambilliotte A, Leverger G, Sommelet D, Lescoeur B, Beaune P, Hémon D, Loriot MA.

Eur J Cancer Prev. 2005 Dec;14(6):531-40.

PMID:
16284498
24.

The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.

Marot D, Opolon P, Brailly-Tabard S, Elie N, Randrianarison V, Connault E, Foray N, Feunteun J, Perricaudet M.

Gene Ther. 2006 Feb;13(3):235-44.

PMID:
16208422
25.

[A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers].

Feunteun J.

J Soc Biol. 2004;198(2):123-6. Review. French.

PMID:
15368961
26.

Sex ratio among the offspring of BRCA mutation carriers.

Feunteun J, Chompret A, Helbling-Leclerc A, Stoppa-Lyonnet D, Belotti M, Noguès C, Bonaïti-Pellié C.

JAMA. 2004 Aug 11;292(6):687-8. No abstract available.

PMID:
15304464
27.

X-chromosome genetics and human cancer.

Spatz A, Borg C, Feunteun J.

Nat Rev Cancer. 2004 Aug;4(8):617-29. Review. No abstract available.

PMID:
15286741
28.

Sex differences in cancer risk among germline p53 mutation carriers.

Chompret A, Brugières L, Bonaïti-Pellié C, Feunteun J.

Br J Cancer. 2004 Aug 2;91(3):603-4. No abstract available.

29.

FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia.

Raslova H, Komura E, Le Couédic JP, Larbret F, Debili N, Feunteun J, Danos O, Albagli O, Vainchenker W, Favier R.

J Clin Invest. 2004 Jul;114(1):77-84.

30.

Association of BRCA1 with the inactive X chromosome and XIST RNA.

Ganesan S, Silver DP, Drapkin R, Greenberg R, Feunteun J, Livingston DM.

Philos Trans R Soc Lond B Biol Sci. 2004 Jan 29;359(1441):123-8.

31.

Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy.

Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K, Horne D, Feunteun J, Lenoir G, Medema R, Vainchenker W, Kroemer G.

Oncogene. 2004 May 27;23(25):4362-70.

PMID:
15048075
32.

The human nuclear SRcyp is a cell cycle-regulated cyclophilin.

Dubourg B, Kamphausen T, Weiwad M, Jahreis G, Feunteun J, Fischer G, Modjtahedi N.

J Biol Chem. 2004 May 21;279(21):22322-30. Epub 2004 Mar 11.

33.

Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France.

Shojaei-Brosseau T, Chompret A, Abel A, de Vathaire F, Raquin MA, Brugières L, Feunteun J, Hartmann O, Bonaïti-Pellié C.

Pediatr Blood Cancer. 2004 Jan;42(1):99-105.

PMID:
14752801
34.

Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells.

Tourneur L, Mistou S, Michiels FM, Devauchelle V, Renia L, Feunteun J, Chiocchia G.

Oncogene. 2003 May 8;22(18):2795-804.

PMID:
12743602
35.

Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.

Bougeard G, Brugières L, Chompret A, Gesta P, Charbonnier F, Valent A, Martin C, Raux G, Feunteun J, Bressac-de Paillerets B, Frébourg T.

Oncogene. 2003 Feb 13;22(6):840-6.

PMID:
12584563
36.

Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.

Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, Guilhot F, Turhan AG, Feunteun J, Bourhis J.

Blood. 2003 Jun 1;101(11):4583-8. Epub 2003 Feb 6.

37.

BRCA1 supports XIST RNA concentration on the inactive X chromosome.

Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, Feunteun J, Livingston DM.

Cell. 2002 Nov 1;111(3):393-405.

38.

Megakaryocyte polyploidization is associated with a functional gene amplification.

Raslova H, Roy L, Vourc'h C, Le Couedic JP, Brison O, Metivier D, Feunteun J, Kroemer G, Debili N, Vainchenker W.

Blood. 2003 Jan 15;101(2):541-4. Epub 2002 Sep 5.

39.

Identification and characterization of Moca-cyp. A Drosophila melanogaster nuclear cyclophilin.

Cavarec L, Kamphausen T, Dubourg B, Callebaut I, Lemeunier F, Métivier D, Feunteun J, Fischer G, Modjtahedi N.

J Biol Chem. 2002 Oct 25;277(43):41171-82. Epub 2002 Aug 1.

40.

Thirteenth annual pezcoller symposium: focusing analytical tools on complexity in cancer.

Mihich E, Feunteun J, Friend S.

Cancer Res. 2002 Jul 1;62(13):3883-7.

41.

A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining.

Baldeyron C, Jacquemin E, Smith J, Jacquemont C, De Oliveira I, Gad S, Feunteun J, Stoppa-Lyonnet D, Papadopoulo D.

Oncogene. 2002 Feb 21;21(9):1401-10.

42.

Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G.

Cancer Res. 2002 Feb 1;62(3):764-72.

43.

BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.

Randrianarison V, Marot D, Foray N, Cabannes J, Méret V, Connault E, Vitrat N, Opolon P, Perricaudet M, Feunteun J.

Cancer Gene Ther. 2001 Oct;8(10):759-70.

44.

[Li-Fraumeni syndrome: update, new data and guidelines for clinical management].

Frebourg T, Abel A, Bonaiti-Pellie C, Brugières L, Berthet P, Bressac-de Paillerets B, Chevrier A, Chompret A, Cohen-Haguenauer O, Delattre O, Feingold J, Feunteun J, Frappaz D, Fricker JP, Gesta P, Jonveaux P, Kalifa C, Lasset C, Leheup B, Limacher JM, Longy M, Nogues C, Oppenheim D, Sommelet D, Soubrier F, Stoll C, Stoppa-Lyonnet D, Tristant H.

Bull Cancer. 2001 Jun;88(6):581-7. Review. French.

45.

Sensitivity and predictive value of criteria for p53 germline mutation screening.

Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pagés S, Feunteun J, Bonaïti-Pellié C.

J Med Genet. 2001 Jan;38(1):43-7. No abstract available.

46.

The hamster polyomavirus--a brief review of recent knowledge.

Scherneck S, Ulrich R, Feunteun J.

Virus Genes. 2001 Jan;22(1):93-101. Review.

PMID:
11210944
47.

BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells.

Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J, Sarasin A.

Cancer Res. 2000 Oct 1;60(19):5548-52.

48.

P53 germline mutations in childhood cancers and cancer risk for carrier individuals.

Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frébourg T, Lemerle J, Bonaïti-Pellié C, Feunteun J.

Br J Cancer. 2000 Jun;82(12):1932-7.

49.

Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2.

Foray N, Randrianarison V, Marot D, Perricaudet M, Lenoir G, Feunteun J.

Oncogene. 1999 Dec 2;18(51):7334-42.

50.

p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.

Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J, Malkin D, Li FP.

Oncogene. 1999 Jul 8;18(27):3970-8.

Supplemental Content

Loading ...
Support Center